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Abstract
The peptiCKDdb is a publicly available database platform dedicated to support re-
search in the field of chronic kidney disease (CKD) through identification of novel bio-
markers and molecular features of this complex pathology. PeptiCKDdb collects pep-
tidomics and proteomics datasets manually extracted from published studies related
to CKD. Datasets from peptidomics or proteomics, human case/control studies on
CKD and kidney or urine profiling were included. Data from 114 publications (studies
of body fluids and kidney tissue: 26 peptidomics and 76 proteomics manuscripts on
human CKD, and 12 focusing on healthy proteome profiling) are currently deposited
and the content is quarterly updated. Extracted datasets include information about
the experimental setup, clinical study design, discovery-validation sample sizes and
list of differentially expressed proteins (P-value< 0.05). A dedicated interactive web
interface, equipped with multiparametric search engine, data export and visualization
tools, enables easy browsing of the data and comprehensive analysis. In conclusion,
this repository might serve as a source of data for integrative analysis or a knowl-
edgebase for scientists seeking confirmation of their findings and as such, is expected
to facilitate the modeling of molecular mechanisms underlying CKD and identification
of biologically relevant biomarkers.
VC The Author(s) 2016. Published by Oxford University Press. Page 1 of 10
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Chronic kidney disease (CKD), a global public health
problem, is a condition characterized by a gradual loss of
kidney function over time (1). CKD comprises a group of
glomerular diseases and is associated with and/or caused
by comorbidities such as diabetes mellitus or hypertension,
therefore the pathophysiology is very complex. CKD is a
highly heterogeneous disease with regards to the cause of
pathology, extent of kidney damage, progression rate and
co-existing conditions (2). Glomerular filtration rate (GFR
[mL/min/1.73 m2]) is an established method for assessment
of kidney function, whereas albuminuria and proteinuria
are indicative of kidney damage (3). Nevertheless, current
clinical biomarkers are of low predictive value, especially
in the early stages of the disease and thus, only advanced
kidney dysfunction is accurately diagnosed, when treat-
ment options are already limited (4). Moreover, given the
complexity of disease processes and the multiple factors
that affect progression over time, there is a great need for
novel biomarkers that might provide insights into disease
mechanisms and improve diagnosis and prognosis of pa-
tients. The advent of high throughput approaches, such as
genomics, transcriptomics, proteomics and metabolomics,
has stimulated many efforts to establish biomarkers or bio-
marker panels of renal disease.
Analysis of human proteome provides a ‘snapshot’ of
the current state of the organism, reflecting the influence of
diet, drugs or disease. Through comparison of healthy and
diseased proteomes, deregulated molecular pathways can
be identified, consequently leading to the elucidation of
pathological mechanisms and the discovery of disease-
associated proteins (5). Mass spectrometry-based (MS)
proteomics enables the investigation of the human prote-
ome in a variety of specimens such as tissue or body fluids
(e.g. plasma, urine, saliva). Many putative biomarkers of
kidney disease have been proposed using these approaches
(6). However, high-throughput data resulting from MS ex-
periments are often underexploited due to the high number
of potential targets of interest.
Therefore, data mining and integration strategies aim at
offering novel insights through collective analysis of infor-
mation gathered from multiple sources, forming a unified
view and ultimately, a better understanding of the studied
system, phenomenon etc. An increasing number of scientific
publications and high-throughput datasets do not contribute
significantly to scientific advances, because they are not sup-
ported by data curators, databases and bioinformatics
analyses (7). Hence, curation and sharing of the data among
the scientific community is crucial, as it assures data usabil-
ity, facilitates integration, encourages collaboration and
thus, leads to novel discoveries (8). Specialized scientific
databases of curated information, which have proliferated
over the last decade, largely facilitate this process and con-
tribute to knowledge generation (9).
Presently, three omics databases exist in the field of kid-
ney disease, namely, ‘Chronic Kidney Disease database’
(CKDdb) (10), the ‘Human Urinary Proteome Fingerprint
Database’ (UPdb) (11) and ‘The Kidney and Urinary
Pathway Knowledge Base’ (KUPKB) (12), providing public
access to existing peptidomics or proteomics datasets and
mining tools (13). However, both multi-omics resources
CKDdb and KUPKB, completely lack data provided from
peptidomic approaches, whereas UPdb stores mass peak in-
formation (m/z values), but peptide or protein information
is rarely assigned. Therefore, currently there is no database
focusing specifically on a comprehensive representation of
peptide sequences and proteomics data that would enable
rapid and interactive evaluation of deposited data. The aim
of the current project was the development of an open-
source peptide- and protein-centric resource, collecting data-
sets extracted from the state-of-the-art publications related
to chronic kidney disease (CKD). To the best of our know-
ledge, the peptiCKDdb is a unique resource that puts em-
phasis on accurate peptidomics and proteomics data
representation and utilization, through comprehensive de-
sign of the database structure to encompass all the data- and
study-specific information and through implementation of
an advanced search engine to perform complex data queries.
An interactive graphical interface equipped with table ma-
nipulation tools (filtering, ordering and data export) and re-
sponsive charts to visualize data, allows for efficient and
intuitive exploration of the data and ‘at-a-glance’ interpret-
ation of query results. This repository should serve as a
knowledge base for scientists seeking confirmation of their
findings or a source of data for integrative analysis and as
such, is expected to facilitate the modeling of molecular
mechanisms underlying CKD and contribute to identifica-
tion of biologically relevant biomarkers.
Materials and Methods
Literature mining
Collection of the peptidomics and proteomic datasets relevant
to chronic kidney disease (CKD) was initiated via screening
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of scientific literature resource, i.e. PubMed (www.ncbi.nlm.
nih.gov/pubmed). Literature search was performed using key-
words: ‘peptidom* AND kidney disease’, ‘proteom* AND
kidney disease’, ‘biomarker AND kidney disease’, ‘kidney dis-
ease AND spectrom*’, ‘proteom* and nephropathy’,
‘proteom* and lupus nephritis’ (search performed 10/03/16).
Reviews and non-English manuscripts were excluded from
further review. Screening and curation was performed by two
curators. Query results were checked in accordance to several
inclusion criteria, i.e. peptidomics or proteomics case–control
study relative to CKD, only human subjects. Of interest were
studies focusing on CKD or other related conditions that af-
fect the kidneys, such as diabetes mellitus, hypertension,
glomerulonephritis, polycystic kidney disease (PKD), lupus
nephritis (LN) or kidney stones. Systematic reviews, articles
and manuscripts out of scope of the project (e.g. renal carcin-
oma, animal models and non-kidney diseases) were excluded.
Initial screening of manuscripts was based on the title and ab-
stract. Consecutively, manuscript content was checked for
availability of information on differentially expressed pep-
tides/proteins. Importantly, information about peptide se-
quence/protein identification was required to select the
manuscript for data curation. In order to complement the lit-
erature search and identify articles that did not appear in
PubMed search results, publicly available -omics databases
related to kidney pathologies, i.e. the ‘Chronic Kidney
Disease database’ (CKDdb; www.padb.org/ckddb) (10), ‘The
Kidney and Urinary Pathway Knowledge Base’ (KUPKB;
www.kupkb.org) (12) and the ‘Human Urinary Proteome
Fingerprint Database’ (UPdb; www.padb.org/updb) (11)
were screened. A subset of manuscripts in compliance with
inclusion criteria was subjected to data extraction. Figure 1
shows the process of literature mining for retrieval of CKD-
relevant manuscripts.
Database design
The general steps followed in the process of the database
development are presented in Figure 2. Database structure
was designed based on the relational database model. To
ensure precise extraction of study-specific information and
representation of proteomics and peptidomics data an
Entity-Relationship (ER) model was constructed and
tested. Simple representation of database structure is pre-
sented on ER diagram (Supplementary Figure S1). The de-
sign was based on seven separate entities (tables):
• Publication Information—information about the manu-
script (title, authors, journal);
• Experimental Information—experiment setting, peptido-
mics/proteomics platform used in the experiment, disease
etiology, existence of validation;
• Clinical Data—cohort information, number and type of
cases/controls, sample types, sample preparation method;
• Validation—information about validation setting,
applied method(s), number of samples;
• Proteomics—differentially expressed proteins extracted
from selected manuscripts, if available fold change/ratio/
regulation and exact p-value was denoted;
• Peptidomics—differentially expressed peptides extracted
from selected manuscripts, if available fold change/ratio/
regulation and exact p-value was denoted;
• UniProtDB—reference database for protein annotation
(UniProt accession number (AC), UniProt ID). Peptides
were annotated based on the corresponding parent
protein.
Database was implemented in Microsoft SQL Server
(MS SQL Server 2014).
Data extraction, pre-processing and loading
For selected manuscripts, data regarding the study design
and statistically significant results (P-value<0.05, as
denoted in each manuscript) were manually curated. Each
manuscript was thoroughly screened in order to identify all
information in accordance with the database structure, i.e.
experiment setting, cohort and samples, validation, differ-
entially expressed molecules etc. Data pre-processing was
performed to assure common format of identifiers and
high consistency of the extracted data. Pre-processing steps
involved data cleaning, i.e. mapping of identifiers to one
common format, i.e. publicly available UniProt ID, there-
fore if a different type of protein identifier was used in the
manuscript (e.g. IPI), its UniProt equivalent was assigned.
Peptides were annotated based on the UniProt ID of the
corresponding parent protein. Moreover, if fold change/
ratio were available, protein was assigned a regulation
trend (UP/DOWN). Finally, all datasets of differentially
expressed, statistically significant proteins (P-value< 0.05)
were deposited into the database.
Web interface development
Web interface was developed to enable fast querying and
retrieval of the stored data and online access to the data-
base. Web application design was based on the three tier
architecture consisting of three layers, i.e. application,
logic and data. Application tier (presentation interface)
was implemented in HTML, CSS and JavaScript with sup-
port of Bootstrap framework (www.getbootstrap.com) for
responsive design and layouts and DataTables plug-in for
tables’ manipulation (www.datatables.net). Interactive
charts were created with use of amCharts library (www.
amcharts.com). Logic tier (business logic) enabling data
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retrieval was implemented in ASP.NET Web Pages. Data
tier (database) was implemented and managed in MS SQL
Server 2014. Main features of the interface include easy
data browsing, data export features (to XLS/CSV/PDF
data formats), quick and multiparametric search and query
results visualizations.
Results
Literature mining and curation
Literature mining in PubMed resulted in 2691 manu-
scripts. After exclusion of reviews, non-CKD related stud-
ies, animal models etc. (2577 entries excluded) abstracts
were further checked for adequacy with regards to afore-
mentioned criteria. Consequently, 114 manuscripts were
retrieved and selected for data extraction and curation;
these included 26 peptidomics and 76 proteomic publica-
tions related to CKD and 12 manuscripts describing
healthy proteome profiling. Studied sample types include
body fluids, i.e. urine, blood, peritoneal dialysate and kid-
ney tissue. Noticeably, urine-based experiments consist of
almost 70% of all deposited data.
Extracted data cover 30 distinct kidney diseases or kidney
conditions, with majority of manuscripts focusing on diabetic
nephropathy (18%), IgA nephropathy (10%), CKD (10%),
polycystic kidney disease (7%) (Supplementary Table S1). A
total of 415 non-redundant peptide sequences (corresponding
to 77 unique proteins) originate from the peptidomics studies.
Furthermore, 4225 unique protein identifications extracted
from shotgun proteomics experiments are deposited in the
database. Among the most represented peptides in the data-
base [based on the total of 26 peptidomics manuscripts] are
sequences of collagen alpha-1(I), collagen alpha-1(III), alpha-
1-antitrypsin and uromodulin. Most frequent protein findings
from proteomics experiments (88 studies) include Ig kappa
chain V-IV, serum albumin, kininogen-1 and protein AMBP.
Similar results are obtained when comparing frequency distri-
bution of peptides and proteins in different reports (detailed
list of the most represented molecules in the database can be
found in the Supplementary Tables S3–S7).
Database features
The peptiCKDdb is developed to facilitate access to prote-
omics findings in the field of CKD, and therefore support
Figure 1. Process of literature mining for retrieval of CKD-relevant manuscripts.
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research efforts in this area. The main goal of the designed
interface was to enable user-friendly access to data. The
major functionalities implemented in the interface are easy
records browsing, search tools to perform complex queries
on the data and export/visualization features.
Records browsing
Database content is presented with regards to type of ana-
lysis (peptidomics, proteomics and healthy proteome
profiling studies). Disease-specific peptidomics and prote-
omics, and healthy proteome dataset summaries are dis-
played in tables on separate tabs for optimal transparency
(Figure 3A). Each table is equipped with a search option to
quickly shortlist studies of interest. Lists can be exported
to Microsoft Excel, CSV or PDF formats. Each dataset
contains detailed information on the study setup (discov-
ery/validation method used, analyzed sample type) and
clinical cohort information (cases, controls and co-
hort size) and a dataset. In the table, data of differentially
expressed molecules, P-value and regulation are given
(Figure 3B).
Data retrieval
Search capabilities, implemented to enable retrieval of the
data from the database, offer a range of possibilities to
query the database. ‘Quick Search’ allows for fast retrieval
of information about peptides and proteins of interest by
entering protein name, UniProt ID, UniProt AC or gene
name. Multi-parametric search was designed to handle
complex queries and precisely set the search criteria. Users
of the database are able to browse the literature data based
on the protein name (UniProt ID/AC), peptide sequence in
case of peptidomics data, gene name, specific disease or
sample type. Batch search enables search for multiple pep-
tide sequences or proteins of interest (Figure 4A). Query re-
sults are displayed in the form of searchable tables, with
possibility of manipulation (column/content ordering, col-
umns’ visibility and data export).
Visualization
Query results are visualized in the form of charts in order
to facilitate interpretation of the results (Figure 4B). For
each search, query output is presented as occurrence of
searched protein(s) per disease and collectively reported
regulation (UP/DOWN) for all results.
Export features
Studies lists, extracted datasets as well as query results can
be easily exported to Microsoft Excel, CSV or PDF file for-
mats. Subsequently, datasets can be further analyzed or
integrated with the use of external tools.
Figure 2. Steps followed in the database development workflow.
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Figure 3. The peptiCKDdb database functionality—record browsing. (A) View of the interface for records browsing and (B) screenshot of the Details
view presenting information extracted from one manuscript.
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Multiple possible applications of database utility in data
exploration can be listed. As an example, analysis of the
peptide sequences with tools for protease prediction such
as Proteasix (14) might be helpful in prediction of molecu-
lar mechanisms of disease and prediction of drug targets.
Moreover, through comparison of urine and kidney
proteome we can identify proteins of intracellular origin
present in urine, which may be of interest when studying
disease-specific processes. Using deposited data, we com-
pared 750 differentially expressed proteins identified in
urine and 553 unique proteins found in the kidney tissue
(proteomics experiments). We present an overlap of 177
proteins (15.7%), for which cellular localization was re-
ported (data from UniProt database). In the overlapping
protein fraction63% of molecules were secreted
and37% were found to be intracellular proteins
(Supplementary Table S2).
Analysis of proteins regulation with regards to sample
type revealed consistent regulation trend in 74.8% of urin-
ary proteins, 93.6% of kidney proteins in kidney and
91.9% of blood proteins. Therefore, we can notice that
regulation of proteins in blood and kidney is consistent, yet
the reproducibility in urine is lower (Supplementary Figure
S2). Therefore, when exploring the regulation trends it is
important to take into account the variability of the pro-
tein expression within different disease etiologies, which
can offer further insights into disease-associated activities.
Examples of such disease-specific regulation trends for IgA
nephropathy (IgAN) and diabetic nephropathy (DN) pre-
sented in the Supplementary data (Supplementary Figures
S3 and S4, Supplementary Tables S8 and S9).
Given the plethora of studies aiming at the description
of a healthy human proteome, we combined the identified
molecules in an attempt to define urinary proteome of
healthy subjects. In addition, we performed the compari-
son of proteins identified in urine and exosomes, which
showed an overlap of 32.3% between both groups
(Supplementary Table S10).
As a proof of concept, we showcase the use of the plat-
form to prove the benefits of meta-analysis of consolidated
data or rapid extraction of biomarker information in
search for potential biomarkers of chronic kidney disease.
Therefore, proteomics and peptidomics profiles were
Figure 4. The peptiCKDdb database functionality—multiparametric search allows for selection of specific query criteria, such as protein name/ID/se-
quence, disease, sample type, present validation (A). Query results are visualized in form of graphs (1) showing distribution of proteins yielded in
search among different diseases and (2) collective regulation of proteins in different studies (B).
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compared, aiming at identification of unique features asso-
ciated with each disease. These features might be disease-
specific putative biomarkers. Figure 5 summarizes the
number of unique proteins and peptide sequences associ-
ated with each disease reported in the database. Although
detailed investigation is needed to assess the feasibility of
these substances as markers, this comparison demonstrates
that the analysis of integrated data contributes to bio-
marker research through selection of distinctive features.
Furthermore, we explored the unique molecules identi-
fied in the studies on diabetic nephropathy (DN). Based on
the collected data, 27 proteins and 15 peptide sequences,
originating from 12 different proteins were found uniquely
associated with DN. Substances are visualized on a den-
drogram (Figure 6). Among them kidney (18), urine (5)
and plasma (4) proteins, and urine peptides were differenti-
ated (15). Upregulation of majority of kidney derived-
proteins suggests the presence of ongoing processes in the
kidney. Importantly, among the molecules, six out of seven
proteins having catalytic activity [e.g. breast cancer type 2
susceptibility protein (BRCA2), glycerophosphodiester
phosphodiesterase 1 (GDE1), MAGUK p55 subfamily
member 2 (MPP2)] and 1 transcription factor, i.e. B-cell
lymphoma 3 protein (BCL3) are overexpressed. All unique
plasma proteins are involved in immune system processes
and upregulated, possibly reflecting an overall
inflammatory state. Among the urinary proteins, histone-
lysine N-methyltransferase 2C (KMT2C) and complement
C1q-like protein 4 (C1QL4) might be of interest since they
are both overexpressed in DN and involved in regulating
fibroblasts proliferation. Considering urinary peptides,
extracellular matrix (ECM) components such as collagens
are found underrepresented, which is in line with the fact
that there is an increased accumulation of ECM in kidney
fibrosis (15). Remaining upregulated protein fragments are
related to inflammation [i.e. inter-alpha-trypsin inhibitor
heavy chain H4 (ITIH4), kininogen-1 (KNG1)] and cellu-
lar processes [e.g. protocadherin Fat 2 (FAT2)].
Collectively, molecules identified in the analysis are poten-
tially functionally implicated in characteristic processes
related to kidney pathology and might be relevant in rela-
tion to diabetic nephropathy. Further investigation is
required to assess the validity of those substances as puta-
tive biomarkers. Overall, these examples are confirming
the usability of the peptiCKDdb database in biomarker
screening.
Discussion and Conclusions
Chronic kidney disease (CKD) is a multi-faceted and highly
complex disease, thus elucidation of pathological mechan-
isms is a real challenge, given the broad range and diversity
Figure 5. Unique features (peptide sequences and proteins) identified for each disease instance present in the database.
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of distinctive molecular characteristics (16). Based on the
high-throughput proteomics experiments, many putative
biomarkers of CKD have been identified, shedding some
light on the disease processes. However, in majority, their
applicability in clinical settings requires further investiga-
tion (17). Therefore, data curation and organization is ne-
cessary for effective analysis and confirmation of results.
Moreover, collective analysis of data across multiple re-
search experiments has a high impact on scientific discov-
ery of biomarkers based on the use of bioinformatics tools
(e.g. for statistics, pathway analysis) and systems biology
approaches (e.g. multi-omics integration for molecular
interactome assembly) (13, 18).
To demonstrate one of the possible applications of the de-
veloped platform in biomarker research, we used deposited
data to explore the proteomic and peptidomic signatures
associated with the underlying causes of CKD. Based on this
proof-of-concept, we identified molecular signatures poten-
tially unique, and seemingly functionally relevant, to diabetic
nephropathy confirming the usefulness of the established
database in rapid extraction of biomarker data and emphasiz-
ing the advantages of consolidated data exploration.
Figure 6. Dendrogram representing peptides and proteins found differentially expressed in different sample types (urine, blood, kidney) and identi-
fied as uniquely associated with diabetic nephropathy (DN). Arrows represent reported regulation between cases and controls (" -upregulation, # -
downregulation).
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The peptiCKDdb database described here is an inte-
grated resource of published peptidomics/proteomics data-
sets developed to support research efforts in the field of
chronic kidney disease. Currently, 114 manually curated
datasets are extracted from the published literature on
CKD and deposited in the database. Those include studies
of body fluids (urine, blood, peritoneal dialysate) and kid-
ney tissue, however, the significantly higher number of the
urine-based experiments may originate from the fact that
kidney tissue is often hard to obtain, contrary to body flu-
ids. Moreover, current efforts in the biomarker research
are focused on the identification of non-invasive markers,
thus sample types which are easily accessible are frequently
exploited. Comprehensive design of the database structure
assures an accurate representation of deposited data.
Furthermore, a dedicated web interface enables fast and in-
formative information retrieval. Therefore, we conclude
that this development fills the gap in the kidney disease re-
search, being an easy-to-use and efficient tool to manage
and mine high-throughput peptidomics and proteomics
datasets. Future work will focus mainly on periodic up-
dates, maintenance of the database content and improve-
ment of the interface through the development of data
mining tools for initial data analysis.
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